



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



MMRi62

Item No. 40841

CAS Registry No.: 352693-80-2
Formal Name: 7-[(2,3-dichlorophenyl)(2-pyridinylamino)methyl]-8-quinolinol
MF: C₂₁H₁₅Cl₂N₃O
FW: 396.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MMRi62 is supplied as a solid. A stock solution may be made by dissolving the MMRi62 in the solvent of choice, which should be purged with an inert gas. MMRi62 is soluble in the organic solvent DMSO at a concentration of approximately 10 mg/ml.

Description

MMRi62 is a degrader of murine double minute 2 (MDM2) and MDM4.¹ It induces ubiquitination of MDM2 and MDM4 in NALM6 leukemia cells when used at a concentration of 5 μM and selectively decreases the proliferation of MV4-11 leukemia cells (IC₅₀ = ~0.12 μM) over primary human peripheral blood mononuclear cells (PBMCs; IC₅₀ = ~15 μM). MMRi62 decreases the growth of HL-60 promyeloblast leukemia cells and multidrug-resistant HL-60/DOX cells (IC₅₀s = 0.34 and 0.22 μM, respectively). It induces apoptosis in MV4-11 cancer cells when used at a concentration of 2 μM. MMRi62 decreases the number of colony-forming units (CFUs) in a panel of ten primary patient-derived leukemia cells expressing either wild-type or mutant p53 with mean IC₅₀ values of 11.7 and 12.8 μM, respectively. *In vivo*, MMRi62 (100 mg/kg per day) decreases tumor size in a HL-60/DOX mouse model of drug-resistant leukemia.

Reference

1. Lama, R., Xu, C., Galster, S.L., *et al.* Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. *Front. Oncol.* **12**, 933446 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/17/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM